chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Pyrexia, Rash, Respiratory tract congestion
Clinical narrative: Severe migraine; Nausea; Abdominal cramping; Burning skin rash on face & chest & hot to touch purple rash on both arms below injection site; Burning skin rash on face & chest & hot to touch purple rash on both arms below injection site; Skin sensitivity with itching burning sensation over most of body; Skin sensitivity with itching burning sensation over most of body; Skin sensitivity with itching burning sensation over most of body; Chest congestion; Cough; Esophageal spasm; Trouble swallowing; Diarrhea; Chills; Fever; Fatigue; Bone & muscle pain; Bone & muscle pain; Emotional upset; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 08Apr2021 at 12:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and lyme disease. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 08Mar2021 at 13:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. On 08Apr2021 at 18:00, the patient experienced severe migraine, nausea and abdominal cramping, burning skin rash on face and chest and hot to touch purple rash on both arms below injection site, skin sensitivity with itching burning sensation over most of body, chest congestion and cough, esophageal spasm and trouble swallowing, diarrhea, chills, fever, fatigue, bone and muscle pain and emotional upset. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe migraine, nausea, abdominal cramping, burning skin rash on face and chest and hot to touch purple rash on both arms below injection site, skin sensitivity with itching burning sensation over most of body, chest congestion, cough, esophageal spasm, trouble swallowing, diarrhea, chills, fever, fatigue, bone and muscle pain and emotional upset was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Decreased appetite, Dyspnoea, Musculoskeletal stiffness, Peripheral swelling
Clinical narrative: throat on fire; Couldn't breathe very well; Couldn't stay awake; not hungry; No energy; three fingers on right hand were stiff swollen couldn't bend; three fingers on right hand were stiff swollen couldn't bend; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12Apr2021 at 15:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 00:00, the patient experienced throat on fire, couldn't breathe very well, couldn't stay awake, not hungry, no energy, three fingers on right hand were stiff swollen couldn't bend and completely non coherent for the first 24 hours, The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events throat on fire, couldn't breathe very well, couldn't stay awake, not hungry, no energy and three fingers on right hand were stiff swollen couldn't bend was recovered with sequelae on an unknown in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Somnolence, Throat irritation
Clinical narrative: throat on fire; Couldn't breathe very well; Couldn't stay awake; not hungry; No energy; three fingers on right hand were stiff swollen couldn't bend; three fingers on right hand were stiff swollen couldn't bend; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12Apr2021 at 15:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 00:00, the patient experienced throat on fire, couldn't breathe very well, couldn't stay awake, not hungry, no energy, three fingers on right hand were stiff swollen couldn't bend and completely non coherent for the first 24 hours, The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events throat on fire, couldn't breathe very well, couldn't stay awake, not hungry, no energy and three fingers on right hand were stiff swollen couldn't bend was recovered with sequelae on an unknown in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Nausea
Clinical narrative: Diarrhea; Nausea; This is a spontaneous report from non-contactable consumer, the patient. A 28-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EVV0153) via an unspecified route of administration in the arm left on 13Apr2021 at 15:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The medical history included ehlers danlos hyper mobile type, postural orthostatic tachycardia syndrome (POTS). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The concomitant medications included pregabalin (MANUFACTURER UNKNOWN), Ondansetron hydrochloride (ZOFRAN), ibuprofen (ADVIL), ivabradine hydrochloride (CORLANOR) and codeine phosphate, paracetamol (TYLENOL WITH CODEINE NO 3), all for an unknown indications from an unknown dates and unknown if ongoing. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the arm left on 21Mar2021 at 16:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patient also received previously desogestrel/ethinylestradiol(RECLIPSEN) and amoxicillin/ clavulanate acid(AUGMENTIN) and experienced allergy. On 14Apr2021 at 10:30, the patient experienced diarrhea and nausea. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events diarrhea and nausea was recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Hypoaesthesia, Vaccination site bruising, Vaccination site swelling
Clinical narrative: Had one episode of severe shortness of breath while taking hot shower next morning; hands also went completely numb; Swelling at injection sight; severe bruising; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the arm left on 27Mar2021 at 15:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to vaccination, the patient was diagnosed with COVID-19). The patient had no know allergies. The patient did not take any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021 at 10:00 the patient experienced swelling at injection sight, severe bruising, had one episode of severe shortness of breath while taking hot shower next morning and hands also went completely numb. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling at injection sight, severe bruising, had one episode of severe shortness of breath while taking hot shower next morning and hands also went completely numb was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dizziness, Lip swelling
Clinical narrative: Swollen lips; Lightheaded; Diarrhea; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 15Apr2021 at 10:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 19:45 the patient experienced swollen lips, lightheaded and diarrhea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lips, lightheaded and diarrhea was unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Abdominal pain upper, Chills, Diarrhoea, Hyperhidrosis
Clinical narrative: Abdominal pain; Nausea; Diarrhea; Stomach cramps; Muscle spasms; Chills; Sweats; This is a spontaneous report from a contactable pharmacist, the patient. A 75-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 12Apr2021 at 10:00 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. Medical history included anemia iron deficiency, hypertension (HTN), hypothyroidism and post-menopausal (Post menopause). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. On 15Apr2021 at 13:00, the patient experienced abdominal pain, nausea, diarrhea, stomach cramps, muscle spasms, chills and sweats. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events abdominal pain, nausea, diarrhea, stomach cramps, muscle spasms, chills and sweats were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle spasms, Nausea
Clinical narrative: Abdominal pain; Nausea; Diarrhea; Stomach cramps; Muscle spasms; Chills; Sweats; This is a spontaneous report from a contactable pharmacist, the patient. A 75-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 12Apr2021 at 10:00 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. Medical history included anemia iron deficiency, hypertension (HTN), hypothyroidism and post-menopausal (Post menopause). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. On 15Apr2021 at 13:00, the patient experienced abdominal pain, nausea, diarrhea, stomach cramps, muscle spasms, chills and sweats. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events abdominal pain, nausea, diarrhea, stomach cramps, muscle spasms, chills and sweats were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity, Pyrexia
Clinical narrative: Fever; headache; tiredness; arm pain; This is a spontaneous report from a contactable consumer (patient). A 50-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: EP6955 and expiry date was not reported), via intramuscular, in Arm Left, on 06Apr2021 at 10:00 AM (age at vaccination: 50 years), as dose 2, single dose for COVID-19 immunization at workplace clinic. The patient was not pregnant at the time of vaccination. The patient's medical history and concomitant medications included bupropion hydrochloride (WELLBUTRIN), ethinylestradiol, norgestimate (ORTHO TRI-CYCLEN), and sertraline hydrochloride (ZOLOFT). Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: EP6955 and expiry date was not reported), via intramuscular, in Arm Left, on 16Mar2021 at 10:00 AM, as a single dose for COVID-19 immunization at workplace clinic. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 06Apr2021, the patient experienced fever, headache, tiredness, and arm pain. The patient did not receive treatment for the adverse events. She continued to have side effects until 09Apr2021. Outcome of the events was recovered on 10Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Back pain, Chest pain, Dyspnoea
Clinical narrative: Shooting back pain; Chest pains; Difficulty breathing; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 18:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 19:30, the patient experienced shooting back pain, chest pains and difficulty breathing. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events shooting back pain, chest pains and difficulty breathing was unknown at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Menstrual disorder
Clinical narrative: Accelerated menstrual cycle by one week; This is a spontaneous report from a non-contactable consumer. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medication received within two weeks of vaccination was not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced accelerated menstrual cycle by one week. Therapeutic measures were not taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event accelerated menstrual cycle by one week was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Epistaxis, Fatigue, Headache, Pain in extremity
Clinical narrative: Nose bleed (unusual for me); Extreme fatigue; Headache; Spells of dizziness.; Arm soreness; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 07Apr2021 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 15Mar2021 at 09:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced arm soreness for 2 days. On 08Apr2021, day after vaccination, the patient experienced extreme fatigue and headache and lasted 2 days. Followed by spells of dizziness, exhaustion and headache continues but to lesser extent. On 14Apr2021, the patient experienced nose bleed (unusual for her). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event arm soreness was recovered on an unknown date in Apr2021, after the duration of 2 days and of the events extreme fatigue, headache, spells of dizziness, exhaustion and nose bleed was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Condition aggravated, Cough, Dyspnoea, Hypersensitivity
Clinical narrative: unusual ashma attack lasting couple days; Believed was my allergy or asthma; silly cough that disappeared after couple hrs/2nd vac cough came back following day, got really bad.; Believed was my allergy or asthma; 2nd vac cough came back following day, got really bad. Blieved was my allergy or asthma; breathing was very agitated; This is a spontaneous report from a contactable consumer (patient). A 62-years-old female patient reported for herself that she received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, administered in arm left on 29Mar2021 at 07:30 AM (age at vaccination was 62 years) as DOSE 2, SINGLE for covid-19 immunisation. The patient was not pregnant at the time of vaccination. No other vaccines were received within four weeks prior to the administration of bnt162b2. Medical history included high blood pressure, borderline diabetic; both from an unknown date and unknown if ongoing. Concomitant medications included levothyroxine, losartan, metformin, atorvastatin [Atorvastatin]; all taken within two weeks for an unspecified indication, start and stop date were not reported. The patient previously received bnt162b2 (Batch/Lot number was not reported), via an unspecified route of administration, administered in arm left on 08Mar2021 at 04:45 PM as DOSE 1, SINGLE for covid-19 immunisation and experienced silly cough that disappeared after couple hrs, between 1& 2 the patient unusual had asthma attack lasting couple days. Reported stated that, on 30Mar2021 at 08:00 PM, on 1 & 2 dose the patient had had silly cough that disappeared after couple hrs, between 1 & 2 she unusual had asthma attack lasting couple days. Second vaccination cough came back following day, it got really bad. The patient believed it was her allergy or asthma, treated it but got worst to the point that yesterday she had to go for treatment at MD, because breathing was very agitated and didn't suffer for any type of such extreme asthma. The patient went on the 29Mar2021 for the second dose with no allergies, no asthma, no cough, no nothing, her body was cleared of any kind of symptoms, was not exposed to anything that could start that cough. The patient believed that without doubt the non stop cough appeared after the shot, she was not a doctor but knew how to treat her allergies and asthma that were seasonal, that had been something completely different out of nothing that had happened to her before, to the point that she had to seek professional help more than 2 was after shot. Adverse events resulted in visit to emergency room/department or urgent care. Therapeutic measures were taken as a result of the events. Treatment included steroid injection, antibiotic, prednisone cough suppressant. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient was not tested for COVID-19. Outcome of the events was unknown.  No follow-up attempts are possible. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Disorientation, Hypopnoea, Vaccination site swelling
Clinical narrative: On the 8th day after my 1st dose, the injection site swollen up about the size of a kiwi.; I had shallow breathing; felt like I smoked a joint/disoriented all day long.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8732) via an unspecified route of administration in the left arm on 30Mar2021 at 13:00(at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient had known allergy to penicillin(pcn). It was reported that the patient was healthy and did not have any health issues. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included modafinil (MANUFACTURER UNKNOWN) and quetiapine fumarate (SEROQUEL); both for an unknown indication from unknown date and unknown if ongoing. On 07Apr2021 at 04:00, On the 8th day after her first dose the patient reported that the injection site swollen up about the size of a kiwi, had shallow breathing and felt like she smoked a joint/disoriented all day long. she was completely fine until the 8th day. The 9th day the swelling subsided, but she had been slightly short of breath since then. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site swollen up about the size of a kiwi, shallow breathing and felt like she smoked a joint/disoriented all day long was recovered with sequelae on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Influenza like illness, Lymphadenopathy, Pain
Clinical narrative: After the second dose of the vaccine, I experienced flu like symptoms including aches in my body and most specifically in my joints; After the second dose of the vaccine, I experienced flu like symptoms including aches in my body and most specifically in my joints; After the second dose of the vaccine, I experienced flu like symptoms including aches in my body and most specifically in my joints; I also experienced extreme swelling in my lymph nodes in the left armpit, the same arm as the injection; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 10:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Mar2021 at 10:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 13Apr2021 at 17:00, after the second dose of the vaccine, the patient experienced flu like symptoms including aches in her body and most specifically in her joints and also experienced extreme swelling in her lymph nodes in the left armpit, the same arm as the injection. This was still persisting three days after the vaccine while all other symptoms resided after two days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events after the second dose of the vaccine, she experienced flu like symptoms including aches in her body and most specifically in her joints was recovered on 15Apr2021. The clinical outcome of the event extreme swelling in her lymph nodes in the left armpit, the same arm as the injection was recovering at this time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Body temperature increased, Chills, Dizziness
Clinical narrative: Slightly elevated temperature; Onset within 8 hours: Fever up to 101 Fahrenheit; Extreme chills; Strong joint and muscle pain; Strong joint and muscle pain; Persistent headache; Nauseating; Dizziness; Sweats; Debilitating fatigue; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 13Apr2021 at 17:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included recently diagnosed with high blood pressure but low end of spectrum and known allergies to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included metoprolol succinate (METOPROLOL SUCCER), esomeprazole sodium (NEXIUM) and calcium (CALCIUM SUPP), all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in left arm on 23Mar2021 at 17:30, as a single dose for COVID-19 immunisation. The patient previously received erythromycin (MANUFACTURER UNKNOWN, for unknown indication on an unknown date and experienced drug allergy. On 14Apr2021 at 01:15, onset within 8 hours, the patient experienced fever up to 101 Fahrenheit, extreme chills, strong joint and muscle pain, persistent headache, nauseating, dizziness, sweats and debilitating fatigue. It was reported that the duration was two days. On 16Apr2021, third day, the patient had slightly elevated temperature, headache, sweats and light fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken for the reported events. The clinical outcome of the events fever up to 101 Fahrenheit, extreme chills, strong joint and muscle pain, nauseating and dizziness was recovered on 16Apr2021, after the duration of 2 days, while that of headache, fatigue, sweats and slightly elevated temperature was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Hyperhidrosis, Myalgia, Nausea
Clinical narrative: Slightly elevated temperature; Onset within 8 hours: Fever up to 101 Fahrenheit; Extreme chills; Strong joint and muscle pain; Strong joint and muscle pain; Persistent headache; Nauseating; Dizziness; Sweats; Debilitating fatigue; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 13Apr2021 at 17:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included recently diagnosed with high blood pressure but low end of spectrum and known allergies to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included metoprolol succinate (METOPROLOL SUCCER), esomeprazole sodium (NEXIUM) and calcium (CALCIUM SUPP), all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in left arm on 23Mar2021 at 17:30, as a single dose for COVID-19 immunisation. The patient previously received erythromycin (MANUFACTURER UNKNOWN, for unknown indication on an unknown date and experienced drug allergy. On 14Apr2021 at 01:15, onset within 8 hours, the patient experienced fever up to 101 Fahrenheit, extreme chills, strong joint and muscle pain, persistent headache, nauseating, dizziness, sweats and debilitating fatigue. It was reported that the duration was two days. On 16Apr2021, third day, the patient had slightly elevated temperature, headache, sweats and light fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken for the reported events. The clinical outcome of the events fever up to 101 Fahrenheit, extreme chills, strong joint and muscle pain, nauseating and dizziness was recovered on 16Apr2021, after the duration of 2 days, while that of headache, fatigue, sweats and slightly elevated temperature was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Slightly elevated temperature; Onset within 8 hours: Fever up to 101 Fahrenheit; Extreme chills; Strong joint and muscle pain; Strong joint and muscle pain; Persistent headache; Nauseating; Dizziness; Sweats; Debilitating fatigue; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 13Apr2021 at 17:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included recently diagnosed with high blood pressure but low end of spectrum and known allergies to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included metoprolol succinate (METOPROLOL SUCCER), esomeprazole sodium (NEXIUM) and calcium (CALCIUM SUPP), all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in left arm on 23Mar2021 at 17:30, as a single dose for COVID-19 immunisation. The patient previously received erythromycin (MANUFACTURER UNKNOWN, for unknown indication on an unknown date and experienced drug allergy. On 14Apr2021 at 01:15, onset within 8 hours, the patient experienced fever up to 101 Fahrenheit, extreme chills, strong joint and muscle pain, persistent headache, nauseating, dizziness, sweats and debilitating fatigue. It was reported that the duration was two days. On 16Apr2021, third day, the patient had slightly elevated temperature, headache, sweats and light fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken for the reported events. The clinical outcome of the events fever up to 101 Fahrenheit, extreme chills, strong joint and muscle pain, nauseating and dizziness was recovered on 16Apr2021, after the duration of 2 days, while that of headache, fatigue, sweats and slightly elevated temperature was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Lip swelling, Musculoskeletal stiffness, Paraesthesia oral
Clinical narrative: This is a spontaneous report from a contactable healthcare professional (patient). A 48-year-old male patient received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# EP7533), at the age of 48, via an unspecified route of administration, on Apr 12, 2021, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. Prior to the vaccination, patient was not diagnosed with COVID-19. On Apr 13, 2021, patient experienced fever, swelling of lips, tingling sensation of tongue, stiff muscles, painful joints, severe headache and excessive urination. No therapeutic measures taken as a result of the events. Since the vaccination, patient has not tested for COVID-19. The outcome of fever, swelling of lips, tingling sensation of tongue, stiff muscles, painful joints, severe headache and excessive urination: recovering (at the time of this report). No follow-up attempts needed. No further information expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Polyuria, Pyrexia
Clinical narrative: This is a spontaneous report from a contactable healthcare professional (patient). A 48-year-old male patient received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# EP7533), at the age of 48, via an unspecified route of administration, on Apr 12, 2021, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. Prior to the vaccination, patient was not diagnosed with COVID-19. On Apr 13, 2021, patient experienced fever, swelling of lips, tingling sensation of tongue, stiff muscles, painful joints, severe headache and excessive urination. No therapeutic measures taken as a result of the events. Since the vaccination, patient has not tested for COVID-19. The outcome of fever, swelling of lips, tingling sensation of tongue, stiff muscles, painful joints, severe headache and excessive urination: recovering (at the time of this report). No follow-up attempts needed. No further information expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site urticaria
Clinical narrative: Severe hives on shoulder that received shot, neck and face; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant-female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration on 15Apr2021 at 09:15 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included gliclazide (CLARITIN), triamcinolone acetonide (NASACORT) and omeprazole (PRILOSEC) for an unknown indication from an unknown date and unknown if ongoing. On 15Apr2021 at 20:30, the patient experienced severe hives on shoulder that received shot, neck and face. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe hives on shoulder that received shot, neck and face was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Cough, Fatigue, Hyperhidrosis
Clinical narrative: Fever; Sweats; Chills; Extreme tiredness; Migraine; Weakness; Cough; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 13Apr2021 at 10:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included crohn's, asthma, spasmodic dysphonia, depression, anxiety and post-traumatic stress disorder (PTSD). The patient had received medication which was not specified within two weeks of vaccination for unknown indication and unknown if ongoing. The patient previously took pethidine hydrochloride (DEMEROL), ciclosporin (CYCLOSPORINE), infliximab (REMICADE) and sulfamethoxazole; trimethoprim (BACTRIM) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 19:00, the patient experienced fever, sweats, chills, extreme tiredness, migraine, weakness, cough, nausea. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events fever, sweats, chills, extreme tiredness, migraine, weakness, cough, nausea was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine, Nausea, Pyrexia
Clinical narrative: Fever; Sweats; Chills; Extreme tiredness; Migraine; Weakness; Cough; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 13Apr2021 at 10:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included crohn's, asthma, spasmodic dysphonia, depression, anxiety and post-traumatic stress disorder (PTSD). The patient had received medication which was not specified within two weeks of vaccination for unknown indication and unknown if ongoing. The patient previously took pethidine hydrochloride (DEMEROL), ciclosporin (CYCLOSPORINE), infliximab (REMICADE) and sulfamethoxazole; trimethoprim (BACTRIM) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 19:00, the patient experienced fever, sweats, chills, extreme tiredness, migraine, weakness, cough, nausea. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events fever, sweats, chills, extreme tiredness, migraine, weakness, cough, nausea was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Body temperature increased, Chills, Dyspnoea, Headache
Clinical narrative: 100.5 temperature; Out of breath when "I" talk; Chills; Aches; Headache; DOSE 1: 29Mar2021/ DOSE 2:15Apr2021; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 15Apr2021 at 16:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic reaction to wasp sting (wasp sting allergy), penicillin allergy and contrast media allergy (Allergy to Gadolinium). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks, prior to the vaccination and did not receive any medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 29Mar2021 at 08:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 04:30, the patient experienced 100.5 temperature, was out of breath when she talked, chills, aches and headache. On the same day at 04:30, the patient underwent body temperature test and the result was 100.5 (unspecified units).The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events 100.5 temperature, out of breath when she talked, chills, aches and headache was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Pain
Clinical narrative: 100.5 temperature; Out of breath when "I" talk; Chills; Aches; Headache; DOSE 1: 29Mar2021/ DOSE 2:15Apr2021; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 15Apr2021 at 16:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic reaction to wasp sting (wasp sting allergy), penicillin allergy and contrast media allergy (Allergy to Gadolinium). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks, prior to the vaccination and did not receive any medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 29Mar2021 at 08:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 04:30, the patient experienced 100.5 temperature, was out of breath when she talked, chills, aches and headache. On the same day at 04:30, the patient underwent body temperature test and the result was 100.5 (unspecified units).The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events 100.5 temperature, out of breath when she talked, chills, aches and headache was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.